about
Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected reviewLow Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern MalawiParents' and guardians' perceptions on availability and pricing of medicines and healthcare for children in eThekwini, South Africa - a qualitative study.Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation.Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines.How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.Trade in medicines and the public's health: a time series analysis of import disruptions during the 2015 India-Nepal border blockadeSurveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.Prescribing patterns of rural family physicians: a study in Kermanshah Province, Iran.Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending.Investigating the impact of the universal healthcare coverage programme on community pharmacy practice.Access to medicines: a dead-lock between health and trade!Value-Based Pricing: L'Enfant Terrible?A review of promoting access to medicines in China - problems and recommendations.Policy Change and the National Essential Medicines List Development Process in Brazil between 2000 and 2014: Has the Essential Medicine Concept been Abandoned?Health-industry linkages for local health: reframing policies for African health system strengthening.Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.Applying a health system perspective to the evolving Farmácia Popular medicines access programme in Brazil.Estimated costs of production and potential prices for the WHO Essential Medicines List.Regulatory evaluation of biosimilars throughout their product life-cycle.Digital health technologies to support access to medicines and pharmaceutical services in the achievement of sustainable development goals.Equity in access to non-communicable disease medicines: a cross-sectional study in Kenya.How the Uruguayan Judiciary Shapes Access to High-Priced Medicines: A Critique through the Right to Health Lens.Production costs and potential prices for biosimilars of human insulin and insulin analoguesMaking medicines more accessible in China: An empirical study investigating the early progress of essential medicine systemQuality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspectionsReal-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational StudyGlobal, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
P2860
Q29994765-B56D309E-DB7F-4BCB-B0BE-3005EFB98B3DQ30377168-23D0DF40-D676-4153-A2E5-BB77546578C7Q33814840-404BD3B2-2474-4A8B-B3AC-C9B7174EB68CQ33851099-1C4875B9-381B-41FB-A2F9-18454876B3B5Q38641699-AFF687AD-30BC-472F-98BC-66687DDA8487Q38648419-722E1583-C767-49C4-BF7F-8ACC6243B4F4Q38808074-B13E7516-7FCB-4D0A-856B-42E3D789D5AFQ39072439-7CF15EA0-ECDA-45D3-8A94-CBCDD369EC40Q41501332-17D938E3-1167-460C-81BD-BEE33E09EAA2Q41634918-33D2E1BD-DA41-4A53-AD7B-B81D02BDDBB8Q47107379-58082D18-F256-4C57-AC98-8C5AF4120E5DQ47998668-5531B82F-1FE3-4FF6-A1E2-5BAB98152503Q48224278-0F4B758F-2CD4-424B-9D89-19BE9946CE6DQ49609717-6D5FD8A5-BA9D-46A1-991A-C77EA59B10C0Q49756124-0F443A43-793D-439D-B4C9-1390A3555074Q49842954-AAA6D4F7-78F9-43EC-94DD-A81F7764C404Q50104677-2A265AC1-D34C-4769-9F02-A60DD0D340CEQ52644743-D3117AB9-2B05-48EE-A62C-5D188263DAD6Q52659410-0CC2EEEE-3211-4A1C-ACF2-026E00D6F649Q52661665-B1BE4830-2816-422F-A7FD-5C8E7C53F968Q53699577-029C4DF1-CBE3-429A-9872-BC0E35B5249DQ55034783-D5940E57-5975-4F8B-8206-46674B455DD2Q55292839-AC6E2F4F-3FBB-4B62-9F8B-281B6AF4873FQ55510606-A5D59FD2-84C0-46D9-ADC0-E9E04682469BQ55715917-DD56DAEB-1E45-4212-8A3A-BBC300CE8BDFQ57069643-3C33E716-793F-4175-BF4E-C77DB4BCE5DBQ57171226-9AE954BB-0979-44AA-A849-B3318F8F8157Q58796183-60008354-5354-44CE-B824-3D3A5BA2A297Q58804239-E8C4F6CE-8458-435F-9A9E-8F07A8E4F549Q59137381-EDF4EE03-59B6-4945-BD62-B42C91DC49F4
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Essential medicines for universal health coverage.
@ast
Essential medicines for universal health coverage.
@en
Essential medicines for universal health coverage.
@nl
type
label
Essential medicines for universal health coverage.
@ast
Essential medicines for universal health coverage.
@en
Essential medicines for universal health coverage.
@nl
prefLabel
Essential medicines for universal health coverage.
@ast
Essential medicines for universal health coverage.
@en
Essential medicines for universal health coverage.
@nl
P2093
P50
P1433
P1476
Essential medicines for universal health coverage.
@en
P2093
Andrew L Gray
Anita K Wagner
Bernard Pécoul
Cornelis P de Joncheere
Corrina Moucheraud
Ellen F M 't Hoen
Helene Möller
Lembit Rägo
Margaret A Ewen
Martha Gyansa-Lutterodt
P304
P356
10.1016/S0140-6736(16)31599-9
P407
P50
P577
2016-11-04T00:00:00Z